Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

AbbVie’s stock danced a volatile jig on June 20th, teasing both bulls and bears before landing barely changed at $185.30. The ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Nektar Therapeutics said on Tuesday its experimental eczema drug had met the main goal of a mid-stage study, sending its shares up by more than 140% in premarket trading.In the 393-patient trial, drug ...

ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost ...

US stocks in focus after Iran attacked US bases in Qatar. Investors often turn to dividend stocks for stability amidst ...

AbbVie Inc. (NYSE: ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King ...

The trial judged the tolerability, safety and efficacy of atogepant, at 60 milligrams once daily, compared to the ...

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

AbbVie stock danced a wild intraday tango on Tuesday, only to end up flat-footed at the closing bell. The day’s price swing ...

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment in a head-to ...